Saturday, 25 May 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 25 May 2024
Listen to this story 
News

Biggest PBAC headaches revealed

Posted 17 April 2024 AM

Securing the PBAC's recommendation appears to have been a much tougher battle for some companies over the past four years with seven pharmas suffering a failure rate of 50 per cent or higher, exclusive Pharma in Focus analysis shows.

The analysis looked at company submissions (excluding those classified 'not applicable') between 1 January 2020 to 31 December 2023 and compared those that were recommended to those that failed to get over the line, meaning they were either rejected, deferred or advice was provided.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (20)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (6)

Other (32)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.